United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Chemical Industry News AdvanSix (NYSE: ASIX) FY2025 results show earnings resilience despite flat revenue and cyclical end-market pressure AdvanSix Inc.’s FY2025 results reveal why earnings held up despite flat revenue and weak chemical markets. Find out what this signals for 2026. bySrinathFebruary 21, 2026